CN105829537B - 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 - Google Patents

用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 Download PDF

Info

Publication number
CN105829537B
CN105829537B CN201480062145.2A CN201480062145A CN105829537B CN 105829537 B CN105829537 B CN 105829537B CN 201480062145 A CN201480062145 A CN 201480062145A CN 105829537 B CN105829537 B CN 105829537B
Authority
CN
China
Prior art keywords
mva
ifn
virus
cells
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480062145.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105829537A (zh
Inventor
于尔根·豪斯曼
M·沃尔费斯泰特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN105829537A publication Critical patent/CN105829537A/zh
Application granted granted Critical
Publication of CN105829537B publication Critical patent/CN105829537B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480062145.2A 2013-11-28 2014-11-25 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 Active CN105829537B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005541 2013-11-28
EP13005541.1 2013-11-28
PCT/EP2014/075522 WO2015078856A1 (en) 2013-11-28 2014-11-25 Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors

Publications (2)

Publication Number Publication Date
CN105829537A CN105829537A (zh) 2016-08-03
CN105829537B true CN105829537B (zh) 2020-09-22

Family

ID=49680779

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480062145.2A Active CN105829537B (zh) 2013-11-28 2014-11-25 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体

Country Status (22)

Country Link
US (2) US20160376596A1 (enExample)
EP (2) EP3074517B1 (enExample)
JP (2) JP6641276B2 (enExample)
KR (1) KR102504316B1 (enExample)
CN (1) CN105829537B (enExample)
AU (3) AU2014356546A1 (enExample)
BR (1) BR112016011866A2 (enExample)
CY (1) CY1124707T1 (enExample)
DK (1) DK3074517T3 (enExample)
EA (1) EA039037B1 (enExample)
ES (1) ES2895977T3 (enExample)
HU (1) HUE056105T2 (enExample)
IL (1) IL245509B (enExample)
LT (1) LT3074517T (enExample)
MX (1) MX377258B (enExample)
MY (1) MY188100A (enExample)
NZ (2) NZ719934A (enExample)
PT (1) PT3074517T (enExample)
SI (1) SI3074517T1 (enExample)
UA (1) UA127337C2 (enExample)
WO (1) WO2015078856A1 (enExample)
ZA (1) ZA201603187B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272546B2 (en) * 2017-08-24 2024-01-01 Bavarian Nordic As Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody
SG11202100305SA (en) 2018-07-13 2021-02-25 Univ Arizona State Methods of treating cancer with tnf expressing myxoma virus
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114615988A (zh) 2019-09-02 2022-06-10 亚利桑那州立大学董事会 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP3957322A1 (en) * 2020-08-19 2022-02-23 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant poxviridae vector expressing co-stimulatory molecules
US20240245765A1 (en) * 2021-05-13 2024-07-25 Thomas Jefferson University Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines
CN115043948B (zh) * 2022-06-24 2024-05-28 青岛硕景生物科技有限公司 一种猴痘病毒特异性融合蛋白抗原及其制备方法和应用
GB202407035D0 (en) * 2024-05-17 2024-07-03 Uncommon Bio Ltd RNA constructs with immune blocking agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744900B2 (en) * 1999-04-08 2010-06-29 Novartis Vaccines And Diagnostics, Inc. Enhancement of the immune response for vaccine and gene therapy applications

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5519239A (en) * 1978-07-28 1980-02-09 Green Cross Corp:The Interferon-producing attractant
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU774076C (en) * 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
AU2003249059A1 (en) * 2002-07-24 2004-02-09 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
US20050281782A1 (en) * 2004-06-21 2005-12-22 Howard Kaufman Novel recombinant poxvirus composition and uses thereof
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
WO2006069064A2 (en) * 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
EP2042604A1 (en) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV promoter driven overexpression of recombinant antigens
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744900B2 (en) * 1999-04-08 2010-06-29 Novartis Vaccines And Diagnostics, Inc. Enhancement of the immune response for vaccine and gene therapy applications

Also Published As

Publication number Publication date
CY1124707T1 (el) 2022-07-22
US12644125B2 (en) 2026-06-02
KR20160087814A (ko) 2016-07-22
PT3074517T (pt) 2021-11-03
HUE056105T2 (hu) 2022-01-28
IL245509A0 (en) 2016-06-30
EP3971298A2 (en) 2022-03-23
EA039037B1 (ru) 2021-11-24
EP3074517B1 (en) 2021-08-11
JP7050044B2 (ja) 2022-04-07
UA127337C2 (uk) 2023-07-26
AU2021200985A1 (en) 2021-03-11
DK3074517T3 (da) 2021-11-08
IL245509B (en) 2020-09-30
EP3971298A3 (en) 2022-04-27
ES2895977T3 (es) 2022-02-23
US20160376596A1 (en) 2016-12-29
AU2014356546A1 (en) 2016-06-02
JP2017503479A (ja) 2017-02-02
LT3074517T (lt) 2021-11-25
NZ719934A (en) 2022-10-28
WO2015078856A1 (en) 2015-06-04
NZ759538A (en) 2022-10-28
ZA201603187B (en) 2023-12-20
MX2016006758A (es) 2016-09-06
BR112016011866A2 (pt) 2017-09-26
AU2024202790A1 (en) 2024-07-04
JP6641276B2 (ja) 2020-02-05
KR102504316B1 (ko) 2023-02-24
EP3074517A1 (en) 2016-10-05
CA2929600A1 (en) 2015-06-04
MY188100A (en) 2021-11-18
AU2021200985B2 (en) 2024-02-01
SI3074517T1 (sl) 2021-12-31
CN105829537A (zh) 2016-08-03
US20200325477A1 (en) 2020-10-15
EA201691120A1 (ru) 2016-09-30
MX377258B (es) 2025-03-07
AU2024202790B2 (en) 2026-06-04
JP2020072693A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
AU2021200985B2 (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
US20210299236A1 (en) Methods and Compositions for Enhancing Vaccine Immune Responses
US20170290909A1 (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
HK40072005A (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
CA2929600C (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
HK1226774A1 (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
HK1226774B (en) Compositions and methods for inducing an enhanced immune response using poxvirus vectors
HK40044708A (en) Pr13.5 promoter for robust t-cell and antibody responses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant